Key Points
==========

-   Ingestion of nitrate (NO~3~^−^), found in green leafy vegetables and especially beets, increases the production of nitric oxide (NO).

-   Acute or chronic (NO~3~^−^) intake also improves muscle contractile function in a variety of subject populations, including healthy young and middle-aged individuals, athletes, patients with heart failure, and the elderly.

-   Precisely how dietary (NO~3~^−^) intake enhances the contractile properties of human muscle is still unclear.

-   We hypothesize that such improvements are the result of increased NO bioavailability and hence changes in Ca^2+^ signaling in muscle.

INTRODUCTION
============

In recent years, a burgeoning number of studies have examined the effects of dietary nitrate (NO~3~^−^) on various physiological responses. This is because it is now recognized that inorganic NO~3~^−^ can be a significant source of nitric oxide (NO) in the body (([@bib1]); see as follows). Because NO is a potent vasodilator, work in this area originally focused on changes in blood pressure (*e.g.*, ([@bib2])). In 2007, however, Larsen *et al*. ([@bib3]) reported that ingestion of NO~3~^−^ at a dose of 100 μmol·kg^−1^ per day for 3 d lowered the steady-state rate of O~2~ uptake (V˙O~2~) during submaximal exercise. This O~2~-sparing effect of NO~3~^−^ supplementation (often in the form of beetroot juice (BRJ)) has since been replicated in many, albeit not all ([@bib4]), subsequent investigations, and seems to be especially evident in untrained subjects and during higher intensity exercise (cf. ([@bib5]) for review). Dietary NO~3~^−^ also has been shown to enhance muscle blood flow during exercise in both rats ([@bib6]) and humans ([@bib7]). At least in rats, the relative increase in flow is greatest in primarily fast-twitch muscles with lower baseline blood flows, but is also present, albeit to a lesser extent, in primarily slow-twitch muscles ([@bib6]). Presumably as a consequence of these changes in O~2~ demand and supply, and hence in muscle energetics, dietary NO~3~^−^ improves endurance performance, as measured by average power, or, conversely, time-to-completion, during high-intensity, time trial--type exercise tests by \~2% ([@bib8],[@bib9]). Because of the shallow slope of the exercise intensity-duration relationship beyond the first few minutes, time-to-fatigue during constant-intensity exercise may be enhanced by up to 16% ([@bib5],[@bib6]). For additional discussion of the effects of dietary NO~3~^−^ on the responses to endurance exercise, readers are referred to these recent reviews ([@bib5],[@bib8],[@bib9]).

More recently, dietary NO~3~^−^ (or nitrite (NO~2~^−^)) also has been shown to enhance the inherent contractile properties of human muscle ([@bib10]--[@bib20]). Positive effects have been found in a wide range of subjects, that is, younger untrained individuals ([@bib10]--[@bib12],[@bib14]), trained athletes ([@bib13],[@bib15]--[@bib17]), patients with heart failure (HF) ([@bib18]), and the elderly ([@bib19],[@bib20]), and can occur in the absence of changes in submaximal V˙O~2~ in the same population and even in some of the same individuals (*i.e.*, ([@bib4]) vs ([@bib18])). Furthermore, NO~3~^−^-induced improvements in muscle contractility have been observed even when resistance to fatigue during high-intensity exercise is unaltered ([@bib11],[@bib13]--[@bib15]). These results suggest that the effects of dietary NO~3~^−^ on muscle contractile properties and on V˙O~2~/blood flow/energetics may be due to different physiological/biochemical mechanisms, reflecting the widely varying actions of NO in various tissues, including muscle.

The purpose of the present article is to review the previously mentioned studies of the influence of dietary NO~3~^−^ on the contractile properties of human muscle and to discuss possible mechanisms accounting for such effects. Although animal data are considered, especially in formulating our mechanistic hypotheses, we focus primarily upon humans because 1) most studies of the effects of NO~3~^−^ intake on muscle function have been performed in people and 2) there are significant differences between rodents and humans in dietary NO~3~^−^ metabolism ([@bib21]), NO~3~^−^-induced changes in muscle protein expression ([@bib12],[@bib22]), fiber type-specific regulation of muscle contraction ([@bib23]), and NO production ([@bib24]), etc., that could influence the results of such research. As will be discussed, it is our hypothesis that dietary NO~3~^−^ acutely enhances human muscle function by simultaneously increasing both the free intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) during contractions and the Ca^2+^ sensitivity of the myofilaments themselves (Figure). These twin effects are hypothesized to result from nitrosylation of the ryanodine receptor (RyR) along with increased NO signaling via the canonical soluble guanyl cyclase (sGC)--cyclic guanosine monophosphate (cGMP)--protein kinase G (PKG) pathway. Together, these two mechanisms could explain the dietary NO~3~^−^-induced changes in human muscle contractile properties that have been reported.

![Proposed mechanisms by which dietary NO~3~^−^ influences muscle contractile function in humans. After ingestion, NO~3~^−^ is converted to NO~2~^−^ by bacterial nitroreductases in the oral cavity and endogenous nitroreductases (*e.g.*, xanthine oxidoreductase) in muscle itself. This increase in NO~2~^−^ in turn leads to enhanced production of the free radical NO. Elevated NO bioavailability then results in multiple effects, as shown in the figure. These include nitrosylation of the sarcroendoplasmic reticululm RyR, which increases Ca^2+^ release by "locking" this channel in the open configuration. The subsequent increase in free intracellular \[Ca^2+^\]~i~ contributes to the improvements in twitch force (F~tw~), rate of force development (*d*F/*d*t), estimated maximal shortening velocity (V~max~), and maximal power (P~max~) of muscle that have been observed after dietary NO~3~^−^ intake. Simultaneously, however, the increase in \[Ca^2+^\]~i~ also results in activation of skeletal muscle myosin light chain kinase (skMLCK) via the Ca^2+^-CaM pathway and hence an increase in myosin regulatory light chain phosphorylation (pRLC). This results in greater Ca^2+^ sensitivity of the contractile apparatus, thereby also contributing to the increases in F~tw~, *d*F/*d*t, V~max~, and P~max~. Paralleling these events, the increase in NO also results in activation of sGC and hence an increase in cGMP production. This increase in cGMP stimulates PKG activity, which in turn enhances regulatory light chain phosphorylation and hence Ca^2+^ sensitivity, thus improving muscle contractile function. Finally, also shown are the effects of increased NO on TropI, on the myosin heavy chain, and on the SERCA. An increase in NO can enhance nitrosylation of TropI in fast-twitch (but not slow-twitch) fibers, but this inhibits (lines) Ca^2+^ sensitivity, which is the opposite of what has been observed after dietary NO~3~^−^ supplementation. Similarly, elevation in NO could increase nitrosylation of myosin, but this would diminish, not enhance, muscle contractile function. Elevated NO also can inhibit SERCA directly, but this would also tend to diminish muscle function, by slowing the rate of relaxation and resulting in eventual depletion of sarcoplasmic reticulum Ca^2+^ stores. Thus, these other potential effects of NO cannot explain the dietary NO~3~^−^-induced improvements in contractility that have been found repeatedly. cGMP, cyclic guanosine monophosphate; NO, nitric oxide; NO~2~^−^, nitrite; NO~3~^−^, nitrate; PKG, protein kinase G; RyR, ryanodine receptor; SERCA, sarcoendoplasmic reticulum Ca^2+^ ATPase; sGC, soluble guanyl cyclase.](jes-46-254-g001){#F1}

NO Production in Muscle
-----------------------

Most NO in the body is produced by conversion of L-arginine to citrulline, a reaction catalyzed by NO synthase (NOS) and requiring O~2~ as well as other substrates and cofactors. NOS exists in three isoforms, that is, neuronal (nNOS, or NOS-1), inducible (iNOS, or NOS-2), and endothelial (eNOS, or NOS-3) ([@bib24]). Although all three types are present in muscle, NOS-1 is considered to be the primary source of NO in this tissue, and in rodents, is almost exclusively expressed in fast-twitch muscle fibers ([@bib24]). In humans, however, NOS-1 expression is similar, or even greater, in slow-twitch versus fast-twitch fibers ([@bib24]). NOS activity increases several-fold during muscle contractions, apparently as a result of Ca^2+^-dependent activation of NOS-1, and at least in mice is accompanied by a quantitatively-similar increase in cGMP levels in fast-twitch but not slow-twitch muscle ([@bib24]). This contraction-induced increase in NO production potentially influences numerous aspects of muscle physiology, for example, blood flow, glucose uptake, mitochondrial respiration, etc., via both cGMP-dependent and cGMP-independent pathways ([@bib24]). These effects are beyond the scope of this review and hence will not be considered further here. Conversely, the effects of NO muscle contractile properties are directly relevant and in fact have been studied for many years, primarily in isolated animal muscle using pharmacological inhibitors or activators of NOS. In general, these studies have emphasized the possible suppressive effects of NO on muscle function, especially maximal isometric force (cf. ([@bib25]) for review). As discussed by Maréchal and Gailly ([@bib25]), however, this direct "braking" effect seems to be countered a cGMP-mediated enhancement of maximal shortening velocity, which improves contractile function during twitch or isotonic contractions. The specific pathways by which NO modulates skeletal muscle contraction are considered in greater detail under the *Mechanisms* section.

Dietary NO~3~^−^ as a Source of NO in Muscle
--------------------------------------------

In addition to the NOS pathway, NO also can be produced via a NOS-independent, "backup" pathway, that is, via reduction of NO~3~^−^ to NO~2~^−^ by oral bacteria ([@bib1]) or endogenous nitroreductases (*e.g.*, xanthine oxidase) ([@bib26]), followed by further reduction of NO~2~^−^ to NO within various tissues. As emphasized by Piknova *et al*. ([@bib26]), the latter process would be favored by the low pH and O~2~ tension found in resting and especially contracting muscle. Conversely, NO~2~^−^ and hence NO~3~^−^ can be generated via oxidation of L-arginine-derived NO, or, alternatively, obtained from dietary sources. Indeed, numerous studies have demonstrated that acute ingestion of NO~3~^−^ increases *plasma* NO~3~^−^ and NO~2~^−^ concentrations (*e.g.,* ([@bib2],[@bib3],[@bib10],[@bib12]--[@bib14],[@bib16]--[@bib20])), as well as the levels of NO in expired breath (frequently used as a biomarker of whole-body NO production) ([@bib11],[@bib14],[@bib18],[@bib19]). Until very recently, though, no study had demonstrated directly that dietary NO~3~^−^ supplementation increases *muscle* NO~3~^−^ or NO~2~^−^ levels in either animals or humans. Working in Schechter's laboratory, however, Gilliard *et al*. ([@bib27]) recently reported that feeding rats a high NO~3~^−^ diet for 7 d increased (*P* \< 0.05) muscle NO~3~^−^ and NO~2~^−^ content by \~33% and \>100%, respectively. Acute ingestion of 150 μmol·kg^−1^ (\~12.3 mmol) of NO~3~^−^ has also recently been shown to more than triple (*P* \< 0.001) the NO~3~^−^ content of muscle biopsy samples from older men with diabetes ([@bib28]), although the small size of such samples apparently precluded measurement of NO~2~^−^ content using the standard chemiluminescent approach. Schechter's group has reported also that strenuous endurance exercise results in a dramatic reduction in muscle NO~3~^−^ and NO~2~^−^ levels in rats, which in the absence of NO~3~^−^ intake remain suppressed for at least 12 h ([@bib26]). Taken together, these data indicate that muscle NO~3~^−^ and NO~2~^−^ are both highly responsive to, and highly dependent upon, dietary intake. The effects of dietary NO~3~^−^ on muscle contractile function as discussed as follows are presumably the result of increased NO production via this NOS-independent pathway. However, the precise mechanism by which dietary NO~3~^−^ might alter human muscle contractile properties is still unknown, and direct effects of NO~2~^−^ and other reactive nitrogen species (*e.g.*, peroxynitrite) cannot be ruled out completely.

Dietary NO~3~^−^ and Muscle Contractile Function
------------------------------------------------

In 2012, Hernández *et al*. ([@bib22]) demonstrated that, in mice, 7 d of (NO~3~^−^) supplementation markedly increased the force generated by fast-twitch, but not slow-twitch, muscle during lower frequency electrical stimulation. There were, though, no changes at higher frequencies of stimulation, that is, in tetanic force, or in the rate of force development. The results of this study will be considered in greater detail later. The first *human* study to touch upon the question at hand, however, was that of Fulford *et al*. ([@bib29]), who in 2013 determined the effects of ingesting 10.2 mmol of NO~3~^−^ either acutely or daily for 5--15 d, including on the day of testing, during isometric knee extensor exercise in healthy, untrained young men (Table). This reduced the energetic cost of exercise, as determined using ^31^P magnetic resonance spectroscopy, but maximal voluntary force production was unchanged. No other measurements of muscle function were obtained, however, nor was there any evidence of any chronic effects of NO~3~^−^ supplementation on muscle energetics (*i.e.*, similar results were obtained during all three trials). The latter finding is consistent with the apparent absence of any chronic effects of dietary NO~3~^−^ supplementation on human muscle contractile properties, as will be discussed.

###### 

Studies of the effects of dietary NO~3~− on human muscle contractile properties

![](jes-46-254-g002)

Haider and Folland ([@bib10]) in 2014 were the first to extensively assess the impact of dietary NO~3~^−^ on human muscle contractility, by determining the effects of ingesting 9.7 mmol of NO~3~^−^/d for 7 d, including on the day of testing, on voluntary and electrically stimulated isometric knee extension exercise in healthy, untrained young men. Although no differences were observed during voluntary exercise, small (*i.e.*, 3%--15%), but statistically significant (*i.e.*, *P* \< 0.01--0.05), improvements in twitch force, force at 10 Hz, and force during the first 50 ms of contraction were found during transcutaneous electrical stimulation. Similar, but slightly larger, improvements (*P* \< 0.01--0.05) have since been reported by Whitfield *et al*. ([@bib12]) in healthy, untrained young men ingesting 26 mmol of NO~3~^−^/d for 7 d (including on the day of testing).

The data of Haider and Folland ([@bib10]) and later Whitfield *et al*. ([@bib12]) clearly demonstrate that ingestion of NO~3~^−^ can alter human muscle contractile function, at least during electrically stimulated isometric exercise. In contrast, using very similar methods, Hoon *et al*. ([@bib30]) found no changes in maximal voluntary force or in twitch force, the rate of force development, the rate of relaxation, or in force at 10--100 Hz of electrical stimulation after 3 d of NO~3~^−^ supplementation at (ostensibly) 8.8 mmol·d^−1^ plus 17.6 mmol on the day of testing. (NO~3~^−^ supplementation did attenuate the rate of fatigue development during repetitive stimulation for ≥80 s, but only when blood flow was restricted.) Although it might be tempting to speculate that these largely negative results are due to the shorter supplementation period, this seems unlikely given that improvements in muscle function have been observed even after an acute dose of NO~3~^−^ (see as follows). The reasons why Hoon *et al*. ([@bib30]) did not find any changes in unfatigued muscle are unclear, although it is worth noting that these investigators used a BRJ product of unverified NO~3~^−^ content and did not measure any markers of NO bioavailability (*e.g.*, plasma NO~2~^−^, breath NO).

Given the data previously discussed, it is natural to wonder whether dietary NO~3~^−^ can influence human muscle function during voluntary, dynamic exercise. Indeed, contemporaneous with Haider and Folland's ([@bib10]) research, we used isokinetic dynamometry to address this question in healthy, young and middle-aged men and women ([@bib11]). We found that a single dose of 11.2 mmol of NO~3~^−^ 2--3 h before testing did not increase maximal isometric force or the force (torque) generated at slower velocities of knee extension. Acute NO~3~^−^ ingestion did, however, enhance force at higher velocities, resulting in 11% and 6% increases (both *P* \< 0.05) in calculated maximal speed (Vmax) and power (Pmax), respectively. Subsequently, we found even greater improvements in Vmax and Pmax (*i.e.*, of 12% and 13%, respectively; both *P* \< 0.05) in response to the same dose of NO~3~^−^ in middle-aged patients with HF ([@bib18]), presumably because such patients are NO deficient ([@bib31],[@bib32]). Because NO bioavailability also decreases with age ([@bib33]), we have since examined the effects of acute NO~3~^−^ ingestion on the Vmax and Pmax of the knee extensors of healthy, elderly subjects ([@bib19]). Although preliminary in nature, the data from this study indicate that older subjects also demonstrate improvements in Vmax and Pmax, at least provided that the dose of NO~3~^−^ ingested is \>125 μmol·kg^−1^. The conclusion that NO~3~^−^ ingestion can improve contractile function even in aged muscle is supported by the findings of Justice *et al*. ([@bib20]), who found that daily supplementation with NO~2~^−^ for 10 wk increased (*P* \< 0.01) the rate of force development during voluntary knee extension and flexion in healthy, middle-aged and older men and women. Finally, we have expanded recently upon our original study ([@bib11]) to investigate determinants of interindividual differences in the effects of dietary NO~2~^−^ on muscle function in a larger cohort ([@bib14]). As before, we observed significant increases in Vmax and Pmax (both *P* \< 0.05) in response to NO~3~^−^ intake, with the size of these improvements being positively associated with the magnitude of the increase in plasma NO~2~^−^ concentration (*P* \< 0.01) and possibly female sex (*P* \< 0.08), but not with other parameters, including baseline Vmax or decline in force during a 50 contraction fatigue test (*in vivo* indicators of muscle fiber type distribution).

All of the data described previously were obtained during isolated contractions performed by a single muscle/muscle group acting across a single joint. To determine whether dietary NO~3~^−^ also improves contractile performance during repeated multi-muscle, multi-joint movements, we collaborated with Dr. Jim Martin and Ernie Rimer at the University of Utah to determine the effects of acute supplementation with 11.2 mmol of NO~3~^−^ on performance during inertial load sprint cycling ([@bib15]). Similar to our isokinetic dynamometry results, we found that NO~3~^−^intake increased (*P* \< 0.05) both cycling Pmax and the associated pedaling rate by 6% in a heterogeneous group of endurance and collegiate team sport athletes. These results have since essentially been confirmed by Domínguez *et al*. ([@bib13]), who found that ingestion of 5.6 mmol of NO~3~^−^ 3 h before a Wingate cycling test increased (*P* \< 0.05) peak power by 6%. Time-to-peak power also tended to be reduced (*P* = 0.06). Jonvik *et al*. ([@bib17]) also recently reported that ingestion of 12.9 mmol of NO~3~^−^/d for 6 (including 3 h before testing) significantly (*i.e.*, P \< 0.01) reduced time-to-peak power (by 3%) during Wingate testing of speed skaters, although peak power itself was unchanged.

Along the same lines, Kramer *et al*. ([@bib16]) recently found that ingesting 8 mmol of NO~3~^−^/d for 6 d improved the peak power of male CrossFit athletes during a Wingate test by 7% (*P* \< 0.01), even though it did not alter force during isometric or isokinetic knee extension or flexion at slow velocities. Unlike in other studies, however, subjects were tested ≥24 h after the last dose of NO~3~^−^, after which *plasma* NO~3~^−^ and NO~2~^−^ levels would be expected to have returned to near normal. Nonetheless, it seems unlikely that the results of Kramer *et al*. ([@bib16]) represent any sort of long-term structural adaptation, because similar improvements have been observed after just a single dose of NO~3~^−^ ([@bib13],[@bib15]). Furthermore, recent data from Whitfield *et al*. ([@bib12]) demonstrate that, unlike in mice ([@bib22]), NO~3~^−^ supplementation of humans does not alter the expression of key Ca^2+^ handling proteins in muscle (see *Mechanisms*). Thus, the results of Kramer *et al*. ([@bib16]) are presumably simply the result of a "loading" effect of previous NO~3~^−^ intake on intramuscular NO~3~^−^ and NO~2~^−^ stores, versus any more permanent adaptations in muscle.

Finally, several recent studies of male team sport athletes by Jones *et al*. ([@bib34]--[@bib36]) also provide indirect evidence that dietary NO~3~^−^ can enhance the contractile properties of human muscle. In the first ([@bib34]), ingestion of 12.8 mmol of NO~3~^−^/d for 7 d (including 2.5 h before testing) was shown to improve (*i.e.*, *P* \< 0.05) performance during the early phases of an intermittent sprint cycling protocol designed to mimic the demands of, for example, international field hockey. Similar results were obtained by Wylie *et al*. ([@bib35]) in subjects ingesting 8.2 mmol of NO~3~^−^/d for 5 d (including 2.5 h before testing) and performing repeated 6 s (but not 30 or 60 s) all-out efforts. Finally, in another study ([@bib35]), supplementation with 6.4 mmol of NO~3~^−^/d for 5 d (including 2.5 before testing) was found to improve significantly (*i.e.*, *P* \< 0.05) 0--5 and 5--10, but not 10--20, m split times during an intermittent sprint running test. Although somewhat indirect, the results of these studies are consistent with the dietary NO~3~^−^-induced increases in muscle contractility found both by ourselves ([@bib11],[@bib14],[@bib15],[@bib18],[@bib19]) and others ([@bib10],[@bib12],[@bib13],[@bib16],[@bib17],[@bib20]).

In summary, numerous recent studies have demonstrated that ingestion of NO~3~^−^ significantly enhances muscle contractile function in humans. This effect seems to be the result of an increase in the number of active actomyosin cross-bridges and in the rate of cross-bridge cycling under load, and not an increase in the force generated per active cross-bridge. This interpretation is based upon the improvements observed in isometric twitch force ([@bib10],[@bib12]), rate of isometric force development ([@bib10],[@bib12],[@bib20]), isometric force during low-frequency electrical stimulation ([@bib10],[@bib12]), isokinetic/dynamic force and power during high-velocity muscle shortening ([@bib11],[@bib13]--[@bib17]), and increased estimated maximal speed of shortening ([@bib11],[@bib15],[@bib19]), all in the absence of any significant improvement in the force-generating capacity of muscle during maximal voluntary contractions ([@bib10]--[@bib12],[@bib14],[@bib16],[@bib19],[@bib20],[@bib30]) or at higher frequencies of electrical stimulation ([@bib10],[@bib12]). The specific biochemical mechanisms by which dietary NO~3~^−^ might alter the contractile characteristics of human muscle are considered in greater detail as follows.

Mechanisms
----------

As mentioned previously, using mice, Hernández *et al*. ([@bib22]) were the first to determine the effects of dietary NO~3~^−^ on muscle contractility. Along with the fast twitch fiber-specific changes in function described previously, these authors found that NO~3~^−^ supplementation increased \[Ca^2+^\]~i~ in muscle, both at rest and during tetanic contractions, and also shifted the force-Ca^2+^ relation, resulting in increased force at moderately high, but sub-saturating, Ca^2+^ levels. These effects were ascribed to increased expression of the Ca^2+^-handling proteins calsequestrin (CSQ) and the dihydropyridine (DHPR) receptor. More recently, however, Whitfield *et al*. ([@bib12]) found that NO~3~^−^ supplementation did not alter the expression of CSQ, DHPR, or other Ca^2+^-handling proteins, that is, RyR or the sarcoendoplasmic reticulum Ca^2+^ ATPase (SERCA), in human muscle. Furthermore, changes in protein expression cannot explain the improvements in muscle contractile function that we ([@bib11],[@bib14],[@bib15],[@bib18],[@bib19]) and others ([@bib13]) have observed repeatedly after *acute* NO~3~^−^ ingestion, nor could the changes in CSQ and DHPR reported by Hernández *et al*. ([@bib22]) seemingly explain the altered Ca^2+^ sensitivity that these authors also found.

In the absence of changes in protein expression, Whitfield *et al*. ([@bib12]) speculated that NO~3~^−^-induced improvements in muscle function may be due to enhanced production of reactive O~2~ species. This hypothesis was based on the observations of Andrade *et al*. ([@bib37]), who reported that H~2~O~2~ reduces Ca^2+^ release but increases maximal tetanic force in isolated mouse muscle fibers. However, Whitfield *et al*. ([@bib12]) found no changes in the levels of protein carbonylation or lipid peroxidation or in the ratio of reduced to oxidized glutathione, which would argue against significant changes in cellular redox status. More importantly, dietary NO~3~^−^ actually increases Ca^2+^ release in mice ([@bib22]) and has failed routinely to increase either maximal voluntary or maximal electrically stimulated force in numerous human studies (([@bib10]--[@bib12],[@bib16],[@bib18],[@bib19],[@bib30]); Table), effects that are precisely the opposite of those due to H~2~O~2~ ([@bib37]). Increased production of reactive O~2~ species also cannot account for the improvements in muscle contractility that result from NO~3~^−^ intake.

Given that neither changes in protein expression nor in redox state can seemingly explain dietary NO~3~^−^-induced improvements in human muscle contractile function, what mechanism(s) is (are) responsible? Historically, NO was considered to act exclusively via the sGC-cGMP-PKG pathway ([@bib38]). In the last few decades, however, it has become increasingly recognized that NO also can influence cellular events more directly, either by itself or after nitrosylation or transnitrosylation of thiols, especially cysteine residues of proteins ([@bib39]). In skeletal muscle, however, most non--cGMP-mediated effects of NO are actually inhibitory, that is, they tend to diminish, not enhance, muscle contractile function. For example, it has been shown that NO directly inhibits the activity of SERCA in rabbit fast twitch muscle ([@bib40]). This would be expected to slow the rate of relaxation and limit the amount of Ca^2+^ released (and hence force generated) during subsequent contractions, due to depletion of Ca^2+^ from the sarcoplasmic reticulum. Somewhat along the same lines, high-intensity exercise has been found to stimulate transnitrosylation of myosin in rat fast twitch muscle ([@bib41]), but this inhibited the Mg^2+^ ATPase activity of the protein. All else being equal, this would reduce maximal shortening velocity. Increased NO availability may lead also to reversible transnitrosylation of troponin I (TropI) ([@bib42]), but the consequence of this is a reduction in Ca^2+^ sensitivity of rat and human fast-twitch and no change in slow-twitch fibers. All of these effects (*i.e.*, decline in Ca^2+^ release, decrease in speed of shortening, reduction or no change in Ca^2+^ sensitivity) are the opposite of those that have been observed after dietary NO~3~^−^ supplementation.

In contrast to the inhibitory effects described previously, transnitrosylation of RyR may be one mechanism by which NO could enhance muscle contractile function. This posttranslational modification of the protein enhances Ca^2+^ release ([@bib43]), by increasing the probability of the channel being in the open state ([@bib44]). In particular, at low O~2~ tensions typical of skeletal muscle *in vivo* even submicromolar concentrations of NO will activate type 1 RyRs ([@bib45]), as a result of transnitrosylation of a single cysteine residue ([@bib46]). This blocks the inhibitory effects of calmodulin (CaM) on RyR1, thereby enhancing Ca^2+^ release and force production. Thus, although excessive nitrosylation of RyRs and hence sustained elevations in \[Ca^2+^\]~i~ in muscle are thought to play a key role in exertional heatstroke and malignant hyperthermia ([@bib47]), physiological (rather than pathophysiological) increases in NO and hence in RyR nitrosylation and Ca^2+^ release as a result of dietary NO~3~^−^ intake could be responsible for the accompanying improvements in muscle contractile function. Specifically, under sub-saturating conditions dietary NO~3~^−^-induced increases in \[Ca^2+^\]~i~ ([@bib22]) would enhance twitch force, rate of force development, shortening velocity, and power, whereas no changes would be expected to occur under saturating conditions, for example, during a sustained maximal isometric contraction. These functional changes are, of course, precisely those that have been observed in response to acute and chronic NO~3~^−^ supplementation. An increase in \[Ca^2+^\]~i~ during contractions due to RyR nitrosylation could explain also the increase in Ca^2+^ sensitivity observed by Hernández *et al*. ([@bib22]), by enhancing myosin regulatory light chain phosphorylation (pRLC) via the Ca^2+^-CaM-skeletal muscle myosin light chain kinase (skMLCK) pathway ([@bib23]). Indeed, the effects of dietary NO~3~^−^ on muscle contractile properties are essentially identical to those resulting from increased pRLC ([@bib23]). Together, these two effects (*i.e.*, an increase in \[Ca^2+^\]~i~ and in Ca^2+^ sensitivity, both as a result of RyR nitrosylation) could account for all of the changes in muscle contractile properties that have been observed in response to dietary NO~3~^−^ intake.

Alternatively and in addition, enhanced NO signaling via the original sGC-cGMP-PKG pathway is another possible mechanism by which NO~3~^−^ supplementation improves muscle contractile function in humans. In this scenario, which is based on that originally hypothesized by Maréchal and Beckers-Bleukx ([@bib48]), an increase in NO bioavailability resulting from dietary NO~3~^−^ intake results in activation of sGC, and hence an increase in cGMP production. Increased cGMP levels in turn result in activation of PKG and hence in skMLCK activity, leading to an increase in pRLC. This would enhance Ca^2+^ sensitivity of the contractile apparatus, thereby accounting for all of the *functional* changes mentioned previously. (An increase in skMLCK activity would not explain the increase in Ca^2+^ release reported by Hernández *et al*. ([@bib22]), as the SR is not a target of this enzyme.) In support of this hypothesis, Maréchal and Beckers-Bleukx ([@bib48]) demonstrated that sGC inhibitors or activators respectively diminished or augmented the maximal shortening velocity of mouse muscle without altering maximal isometric force, effects that resemble those of dietary NO~3~^−^. Maréchal and Beckers-Bleukx ([@bib48]) also found that inhibition of NOS reduced basal cGMP levels by 12%--27%, whereas others have reported (in abstract) that NOS inhibition reduces pRLC by a similar amount in C2C12 myotubes ([@bib49]). Thus, although it remains to be demonstrated that an *increase* in NO bioavailability as a result of dietary NO~3~^−^ intake results in an *increase* in either cGMP or in pRLC in either animal or human muscle, this alternative or parallel mechanism may also be operative.

Effects of Muscle Fiber Type
----------------------------

As indicated previously, studies of rodents have demonstrated that the effects of dietary NO~3~^−^ on contractile properties are specific to fast-twitch muscle ([@bib22]). In rats, however, muscle contraction results in an increase in pRLC only in fast-twitch fibers, whereas in humans this occurs in both fast-twitch and slow-twitch fibers ([@bib23]). Furthermore, human (and rat) fast- and slow-twitch muscle fibers primarily or even exclusively express the same isoform of RyR, that is, RyR1 ([@bib50]). Thus, based on the mechanisms described previously, there would be no reason to hypothesize a fiber type-specific effect of dietary NO~3~^−^ on the contractile properties of human muscle, even though one exists in rats. In fact, as previously mentioned, we were recently unable to detect any relation between *in vivo* indicators in muscle fiber type distribution and the magnitude of the dietary NO~3~^−^-inducted increase in Pmax ([@bib14]). Muscle fiber type distribution was not determined directly in this study, however, so at least at present a fiber type-specific benefit of dietary NO~3~^−^ supplementation on human muscle function cannot be ruled out completely.

Significance
------------

Additional research is required to test the previous hypotheses and may prove to be particularly challenging given the previously mentioned differences between humans and rodents, including in the acute responses ([@bib21]) and chronic adaptations (*i.e.*, (12) vs (22)) to dietary NO~3~^−^ supplementation. The "crosstalk" between the proposed RyR and sGC-cGMP-PKG pathways (at the level of pRLC) may also make it difficult to determine the relative importance of nitrosylation versus canonical NO signaling, as is true in other situations. Regardless of the precise mechanism(s) involved, however, the improvements in human muscle contractile function resulting from NO~3~^−^ ingestion are potentially significant. This is true in the contexts of both sports and general health and well-being. For example, as previously discussed ([@bib11]), even a 1% improvement in performance would double the probability of an elite athlete winning a particular competition. Comparatively speaking, the 4%--13% increase in maximal neuromuscular power resulting from dietary NO~3~^−^ intake ([@bib11],[@bib13]--[@bib16],[@bib18],[@bib30]) is enormous. More importantly, muscle power plays a key role in activities of daily living yet is compromised markedly in, for example, patients with HF due to systolic dysfunction ([@bib31]). Indeed, reduced muscle contractile function strongly contributes to the whole-body exercise intolerance that is characteristic of the latter "cardiomuscular" disease, and in fact is a powerful predictor of survival in those with HF ([@bib31]). In this context, as previously discussed ([@bib31]), the magnitude of the dietary NO~3~^−^-induced increase in maximal neuromuscular power we have found in HF patients ([@bib18]) is sufficient to have acutely erased approximately one third of their expected deficit in this parameter. It is also similar to that resulting from 2 to 3 months of resistance exercise training in such individuals, which has been shown to result in improvement in Minnesota Living with Heart Failure Questionnaire Scores ([@bib18]). Thus, significant improvements in skeletal muscle contractility due to NO~3~^−^ ingestion could have a positive impact on quality of life and possibly even lifespan in patients with HF, as well as other subject groups.

Summary
-------

Numerous recent studies, both by ourselves ([@bib11],[@bib14],[@bib15],[@bib18],[@bib19]) and by others ([@bib10],[@bib12],[@bib13],[@bib16],[@bib17],[@bib20]), have demonstrated that acute or chronic NO~3~^−^ (or NO~2~^−^([@bib20])) ingestion significantly enhances the contractile properties of human skeletal muscle, especially speed and hence power. Such improvements have been observed in a wide range of subjects, including younger, untrained individuals ([@bib10]--[@bib12],[@bib14]), trained athletes ([@bib13],[@bib15]--[@bib17]), patients with HF ([@bib18]), and the elderly ([@bib19],[@bib20]). The precise mechanisms responsible for this NO~3~^−^-induced increase in human muscle contractility are still unknown, but changes in Ca^2+^ signaling due to increased NO bioavailability are likely to play a role. Additional research will be needed to test this hypothesis and to determine the practical and clinical benefits of using NO~3~^−^ supplementation to augment muscle function in healthy and diseased populations.
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